Celgene’s recent acquisition offer by Bristol-Myers Squibb has raised attention to its prolific dealmaking history. We covered this in a recent article in Endpoints News. Celgene was also very active in venture round participation. Here’s a quick look at how Celgene ranked in its investment activity since 2010 in venture rounds at cancer therapeutics companies.
Run your own analysis with your DealForma access.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
Specifically for Biotech, Pharma, Device, and Diagnostics
More from the DealForma Blog
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
Global biotechnology venture investment topped $11.8 billion in 258 financing rounds in the first 10 months of 2018. Who are the top biotech venture investors, where are they investing their money, and what are they investing in?
Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.
Pharma deal upfront cash payments made for development and commercialization with biotech, device, diagnostics, and technology platform companies.
Partnering meetings coming up?
With thousands of company profiles and a decade of deals and funding specifically in biotech and pharma, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you be the star of that partnering booth with better data.
DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.
Analysis / Blog